Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: N Engl J Med. 2017 Nov 9;377(19):1836–1846. doi: 10.1056/NEJMoa1701830

Figure 1. Selection of Women with Breast Cancer from 88 Trials of Adjuvant Breast-Cancer Therapy.

Figure 1

The analyses combine individual patient data from 88 trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database of randomized trials. All the women who were included in the study were scheduled to receive adjuvant endocrine therapy for only 5 years, regardless of actual adherence, after a diagnosis of estrogen-receptor (ER)–positive breast cancer before the age of 75 years. A total of 74,194 women who were enrolled in 78 trials at the time of diagnosis were included in the analyses that began at year 0. A total of 62,923 women who were enrolled in 88 trials either at the time of diagnosis or later (having already received 2 to 5 years of endocrine therapy) were scheduled to stop therapy at 5 years and were included in the analyses that began at year 5.